You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

ABLAVAR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ablavar, and when can generic versions of Ablavar launch?

Ablavar is a drug marketed by Lantheus Medcl and is included in one NDA.

The generic ingredient in ABLAVAR is gadofosveset trisodium. Additional details are available on the gadofosveset trisodium profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ABLAVAR?
  • What are the global sales for ABLAVAR?
  • What is Average Wholesale Price for ABLAVAR?
Summary for ABLAVAR
Drug patent expirations by year for ABLAVAR
Recent Clinical Trials for ABLAVAR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Paul FinnPhase 4
Maastricht University Medical CenterPhase 4
Maastricht University Medical Center

See all ABLAVAR clinical trials

US Patents and Regulatory Information for ABLAVAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ABLAVAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ⤷  Sign Up ⤷  Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ⤷  Sign Up ⤷  Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ⤷  Sign Up ⤷  Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ⤷  Sign Up ⤷  Sign Up
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for ABLAVAR

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
TMC Pharma Services Ltd. Ablavar (previously Vasovist) gadofosveset trisodium EMEA/H/C/000601
This medicinal product is for diagnostic use only.Ablavar is indicated for contrast-enhanced magnetic resonance angiography (CE-MRA) for visualisation of abdominal or limb vessels in adults only, with suspected or known vascular disease.
Withdrawn no no no 2005-10-03
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Supplementary Protection Certificates for ABLAVAR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0806968 CA 2007 00016 Denmark ⤷  Sign Up
0806968 C00806968/01 Switzerland ⤷  Sign Up FORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
0806968 SPC/GB07/011 United Kingdom ⤷  Sign Up PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
0806968 300253 Netherlands ⤷  Sign Up 300253, 20160116, EXPIRES: 20201002
0806968 PA2007003 Lithuania ⤷  Sign Up PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REG NO/DATE: EU/1/05/313/001-009 20051005
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.